Kezar Life Sciences Inc (KZR)

Mar 25, 2025, 6:54 PM EDT - 4 weeks ago

Kezar Life Sciences, Inc. (KZR) PORTOLA Topline Phase 2a Results in Autoimmune Hepatitis Conference Call (Transcript)

Mar 25, 2025, 7:30 AM EDT - 4 weeks ago

Kezar Life Sciences Announces Positive Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis (AIH) and Reports Fourth Quarter and Year End 2024 Financial Results

Mar 24, 2025, 8:00 AM EDT - 4 weeks ago

Kezar Life Sciences to Present Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis on March 25, 2025

Feb 18, 2025, 4:01 PM EST - 2 months ago

Kezar Life Sciences to Present at Virtual KOL Event Hosted by William Blair on Zetomipzomib Clinical Development in Autoimmune Hepatitis and Provide a Safety Update from the PALIZADE Trial for Lupus Nephritis on February 27, 2025

Nov 12, 2024, 4:01 PM EST - 5 months ago

Kezar Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 5, 2024, 10:58 AM EST - 6 months ago

Glancy Prongay & Murray LLP Announces Investigation of Kezar Life Sciences, Inc. (KZR)

Oct 28, 2024, 8:30 AM EDT - 6 months ago

Kezar Life Sciences Announces 1-for-10 Reverse Stock Split

Oct 17, 2024, 8:35 AM EDT - 6 months ago

Kezar Board Unanimously Rejects Unsolicited Concentra Proposal and Adopts Limited Duration Stockholder Rights Plan

Oct 17, 2024, 8:30 AM EDT - 6 months ago

Kezar Life Sciences Announces Positive IDMC Safety Review of PORTOLA Trial of Zetomipzomib in Patients with Autoimmune Hepatitis and Provides PALIZADE Update

Oct 10, 2024, 8:30 AM EDT - 6 months ago

Kezar Confirms Receipt of Unsolicited, Non-Binding Acquisition Proposal

Oct 4, 2024, 5:11 PM EDT - 7 months ago

US FDA puts clinical hold on Kezar Life Sciences' lupus treatment trial

Oct 4, 2024, 5:00 PM EDT - 7 months ago

Kezar Life Sciences Announces Clinical Hold of Zetomipzomib IND for Treatment of Lupus Nephritis

Sep 30, 2024, 8:46 AM EDT - 7 months ago

Kezar Life Sciences halts mid-stage trial for lupus treatment

Sep 30, 2024, 8:30 AM EDT - 7 months ago

Kezar Life Sciences Announces Cessation of Enrollment and Dosing in the Phase 2b PALIZADE Trial of Zetomipzomib in Active Lupus Nephritis Patients

Sep 4, 2024, 4:01 PM EDT - 8 months ago

Kezar Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 13, 2024, 4:02 PM EDT - 9 months ago

Kezar Life Sciences Reports Second Quarter 2024 Financial Results and Provides Business Update

Jul 10, 2024, 4:01 PM EDT - 10 months ago

Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

May 29, 2024, 4:01 PM EDT - 11 months ago

Kezar Life Sciences to Participate in the Jefferies Global Healthcare Conference

May 9, 2024, 4:01 PM EDT - 1 year ago

Kezar Life Sciences Reports First Quarter 2024 Financial Results and Provides Business Update

May 6, 2024, 4:05 PM EDT - 1 year ago

Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Mar 14, 2024, 4:01 PM EDT - 1 year ago

Kezar Life Sciences Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Update

Feb 28, 2024, 4:01 PM EST - 1 year ago

Kezar Life Sciences to Participate in the TD Cowen 44th Annual Health Care Conference

Feb 26, 2024, 6:30 PM EST - 1 year ago

Everest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus Nephritis

Nov 21, 2023, 4:01 PM EST - 1 year ago

Kezar Life Sciences to Present at the 6th Annual Evercore ISI HealthCONx Conference

Nov 13, 2023, 4:01 PM EST - 1 year ago

Kezar Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update

Oct 3, 2023, 4:10 PM EDT - 1 year ago

Kezar Life Sciences Announces Strategic Restructuring to Prioritize Clinical-Stage Assets and Extend Financial Runway and Appoints Christopher Kirk, Ph.D. as Chief Executive Officer

Sep 24, 2023, 10:33 PM EDT - 1 year ago

Week In Review: Everest Acquires Novel Autoimmune Therapy In $132 Million Agreement

ONC BMY NVS OCUL

Sep 20, 2023, 6:30 PM EDT - 1 year ago

Kezar Life Sciences and Everest Medicines Enter into an Agreement to Develop and Commercialize Zetomipzomib for Lupus Nephritis and other Potential Indications in Greater China, South Korea and Southeast Asia

Aug 31, 2023, 4:01 PM EDT - 1 year ago

Kezar Life Sciences to Participate in Three Upcoming Investor Conferences

Aug 21, 2023, 7:32 AM EDT - 1 year ago

Top 5 Health Care Stocks That Could Blast Off This Month - Allakos (NASDAQ:ALLK), BioLife Solns (NASDAQ:BLFS)

ALLK BLFS TCRT

Aug 10, 2023, 4:01 PM EDT - 1 year ago

Kezar Life Sciences Reports Second Quarter 2023 Financial Results and Provides Business Update

May 31, 2023, 7:00 AM EDT - 2 years ago

Kezar Life Sciences to Participate in the Jefferies Healthcare Conference

May 11, 2023, 4:01 PM EDT - 2 years ago

Kezar Life Sciences Reports First Quarter 2023 Financial Results and Provides Business Update

Mar 14, 2023, 4:01 PM EDT - 2 years ago

Kezar Life Sciences Reports Fourth Quarter and Year End 2022 Financial Results and Provides Business Update

Mar 13, 2023, 7:00 AM EDT - 2 years ago

Kezar Life Sciences to Change Virtual R&D Day Date to March 15, 2023

Mar 6, 2023, 7:00 AM EST - 2 years ago

Kezar Life Sciences to Host Virtual R&D Day on March 22, 2023

Mar 1, 2023, 4:01 PM EST - 2 years ago

Kezar Life Sciences to Participate in the Cowen 43rd Annual Health Care Conference

Jan 4, 2023, 4:01 PM EST - 2 years ago

Kezar Life Sciences to Present at the 41st Annual J.P. Morgan Healthcare Conference

Nov 16, 2022, 1:23 AM EST - 2 years ago

Kezar Life Sciences: Mid-Term Growth Levers Heavily Discounted, Reduce To Hold

Nov 14, 2022, 7:00 AM EST - 2 years ago

Kezar Life Sciences Presents Positive Complete Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib in Lupus Nephritis at the American College of Rheumatology Convergence 2022

Nov 10, 2022, 4:01 PM EST - 2 years ago

Kezar Life Sciences Reports Third Quarter 2022 Financial Results and Provides Business Update

Nov 9, 2022, 4:01 PM EST - 2 years ago

Kezar Life Sciences to Participate in Two Upcoming Investor Conferences

Nov 3, 2022, 10:00 AM EDT - 2 years ago

Kezar Life Sciences Presents Positive Complete Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib in Lupus Nephritis at ASN's Kidney Week 2022 Annual Meeting

Oct 14, 2022, 7:00 AM EDT - 2 years ago

Kezar Life Sciences to Present Complete Results from the Phase 2 MISSION Trial of Zetomipzomib in Patients with Lupus Nephritis at the American Society of Nephrology's Kidney Week 2022 Annual Meeting

Oct 3, 2022, 4:01 PM EDT - 2 years ago

Kezar Life Sciences Receives FDA Clearance of IND for Zetomipzomib for the Treatment of Autoimmune Hepatitis

Sep 29, 2022, 4:05 PM EDT - 2 years ago

Kezar Life Sciences to Present Complete Results from the Phase 2 MISSION Trial of Zetomipzomib in Patients with Lupus Nephritis at the American College of Rheumatology Convergence 2022

Aug 11, 2022, 4:01 PM EDT - 2 years ago

Kezar Life Sciences Reports Second Quarter 2022 Financial Results and Provides Business Update

Jul 27, 2022, 1:45 PM EDT - 2 years ago

Kezar Life Sciences: Regulatory Tailwinds Reverse Downside Case

Jul 11, 2022, 4:30 PM EDT - 3 years ago

Kezar Life Sciences Appoints Nick Mordwinkin as Chief Business Officer and Reports Updated Cash Position